Denali Therapeutics Inc.
DNLI
$20.57
-$0.13-0.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -512.54M | -498.74M | -479.03M | -453.94M | -422.77M |
| Total Depreciation and Amortization | 14.81M | 13.65M | 12.06M | 10.04M | 8.99M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.98M | 81.63M | 75.10M | 67.54M | 49.15M |
| Change in Net Operating Assets | 149.00K | 5.69M | 42.26M | 10.81M | 16.94M |
| Cash from Operations | -412.60M | -397.78M | -349.62M | -365.54M | -347.69M |
| Capital Expenditure | -9.50M | -13.07M | -18.33M | -18.84M | -15.91M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 264.78M | 419.79M | 460.88M | 402.02M | -72.84M |
| Cash from Investing | 255.28M | 406.72M | 442.55M | 383.18M | -88.76M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.17M | -16.48M | -39.13M | -36.70M | -32.34M |
| Issuance of Common Stock | 925.71M | 9.39M | 14.26M | 16.96M | 517.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -728.32M | 0.00 | 0.00 | 0.00 | -480.00K |
| Cash from Financing | 189.22M | -7.09M | -24.87M | -19.73M | 484.30M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.90M | 1.86M | 68.06M | -2.10M | 47.85M |